Gene · 10643
Papers3,038
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
301 to 320 of 3,038
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Epigenetic control of dental stem cells: progress and prospects in multidirectional differentiation. | Epigenetics Chromatin | 2024 | 39623487 | PubTator, text mining | PubMed |
| Stabilization of SQLE mRNA by WTAP/FTO/IGF2BP3-dependent manner in HGSOC: implications for metabolism, stemness, and progression. | Cell Death Dis | 2024 | 39617776 | PubTator, text mining | PubMed |
| HNRNPH1 stabilizes FLOT2 mRNA in a non-canonical m6A-dependent manner to promote malignant progression in nasopharyngeal carcinoma. | Cell Oncol (Dordr) | 2024 | 39570559 | PubTator, text mining | PubMed |
| FTO suppresses cardiac fibrosis after myocardial infarction via m6A-mediated epigenetic modification of EPRS. | Mol Med | 2024 | 39538146 | PubTator, text mining | PubMed |
| IGF2BP3/CTCF Axis-Dependent NT5DC2 Promotes M2 Macrophage Polarization to Enhance the Malignant Progression of Lung Squamous Cell Carcinomas. | Clin Respir J | 2024 | 39506204 | PubTator, text mining | PubMed |
| IGF2BP3-dependent N6-methyladenosine modification of USP49 promotes carboplatin resistance in retinoblastoma by enhancing autophagy via regulating the stabilization of SIRT1. | Kaohsiung J Med Sci | 2024 | 39497328 | PubTator, text mining | PubMed |
| N6-Methyladenosine modification activates the serine synthesis pathway to mediate therapeutic resistance in liver cancer. | Mol Ther | 2024 | 39489921 | PubTator, text mining | PubMed |
| Biomarker Study for Selecting Neoadjuvant Chemotherapy Regimens Based on Prognostic Prediction Using Gastric Cancer Biopsy Specimens from a Phase II Randomized Controlled Trial. | Anticancer Res | 2024 | 39477312 | PubTator, text mining | PubMed |
| Interactive Structural Analysis of KH3-4 Didomains of IGF2BPs with Preferred RNA Motif Having m6A Through Dynamics Simulation Studies. | Int J Mol Sci | 2024 | 39456902 | PubTator, text mining | PubMed |
| Lactylation-Driven IGF2BP3-Mediated Serine Metabolism Reprogramming and RNA m6A-Modification Promotes Lenvatinib Resistance in HCC. | Adv Sci (Weinh) | 2024 | 39450426 | PubTator, text mining | PubMed |
| m6A-modified exosome-derived circHIF1α binding to KH domain of IGF2BP3 mediates DNA damage and arrests G1/S transition phase to resists bacterial infection in bacteremia. | J Nanobiotechnology | 2024 | 39443946 | PubTator, text mining | PubMed |
| IGF2BP3 boosts lactate generation to accelerate gastric cancer immune evasion. | Apoptosis | 2024 | 39397122 | PubTator, text mining | PubMed |
| Deciphering the IGF2BP3-mediated control of ferroptosis: mechanistic insights and therapeutic prospects. | Discov Oncol | 2024 | 39392532 | PubTator, text mining | PubMed |
| Post-Translational Modifications of RNA-Modifying Proteins in Cellular Dynamics and Disease Progression. | Adv Sci (Weinh) | 2024 | 39377984 | PubTator, text mining | PubMed |
| Multi-omics analysis unveils the predictive value of IGF2BP3/SPHK1 signaling in cancer stem cells for prognosis and immunotherapeutic response in muscle-invasive bladder cancer. | J Transl Med | 2024 | 39367493 | PubTator, text mining | PubMed |
| HSV-1-induced N6-methyladenosine reprogramming via ICP0-mediated suppression of METTL14 potentiates oncolytic activity in glioma. | Cell Rep | 2024 | 39325621 | PubTator, text mining | PubMed |
| The role of KRT7 in metastasis and prognosis of pancreatic cancer. | Cancer Cell Int | 2024 | 39300449 | PubTator, text mining | PubMed |
| Characterizing m6A modification factors and their interactions in colorectal cancer: implications for tumor subtypes and clinical outcomes. | Discov Oncol | 2024 | 39292326 | PubTator, text mining | PubMed |
| Licochalcone A decreases cancer cell proliferation and enhances ferroptosis in acute myeloid leukemia through suppressing the IGF2BP3/MDM2 cascade. | Ann Hematol | 2024 | 39264435 | PubTator, text mining | PubMed |
| Are cities under bright lights more innovative? Evidence from China. | Heliyon | 2024 | 39253158 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/10643/papers?page=16